32 results about "5 Alpha-Reductase Inhibitor" patented technology

This invention provides a composition comprising a 5-alpha reductase inhibitor and a class of androgen receptor targeting agents (ARTA), which are selective androgen receptor modulators (SARM). The compositions of this invention are useful for, inter-alia, a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment of polycystic ovarian disease; e) treatment and/or prevention of acute and/or chronic muscular wasting conditions; f) preventing and/or treating dry eye conditions; g) oral androgen replacement therapy; h) decreasing the incidence of, halting or causing a regression of prostate cancer; and/or i) inducing apoptosis in a cancer cell.

The present invention relates to topical compositions comprising 5α-reductase inhibitors. The present invention also includes processes for preparation of such topical compositions and methods of using them.

This invention describes a new combination for the treatment of functional bladder disorders which comprises an alpha antagonist and/or 5-alpha-reductase inhibitor and a beta-3-adrenoceptor agonist.

The invention provides a new application of lotus plumule, in particular to the application of the lotus plumule, lotus plumule total alkaloid, bisbenzylisoquinoline-(7-0-11')-monoether key alkaloid derivant or analogue in preparing a drug or health care food of 5 alpha-reductase inhibitor. The invention also provides a 5 alpha-reductase inhibitor. The lotus plumule of the invention serves as the 5 alpha-reductase inhibitor and can serve as drug, health care food or food additive. The lotus plumule and the active ingredients thereof of the invention are used for inhibiting 5 alpha-reductase, can reduce prostate gland, can quickly remove the obstruction symptom of benign prostatic hyperplasia, can treat seborrheic alopecia and acne, has specific potency and controllable quality, is safe and provides a new option for clinic.

The invention provides a nano composition containing diaminopyrimidine oxide and pyrrolidinyl diaminopyrimidine oxide and a preparation method and application of the nano composition, and belongs to the technical field of cosmetics with special functions. The provided nano composition comprises the following components in percentages by mass: 5-20% of diaminopyrimidine oxide, 2.5-10% of pyrrolidinyl diaminopyrimidine oxide, 0.1-10% of 5 alpha-reductase inhibitor, 0.1-10% of an androgen receptor antagonist, 0.1-5% of a vasodilator agent, 0.1-10% of an anti-inflammation bacteriostatic agent, 0.1-5% of an antioxidant, 0.5-10% of phospholipid, 0.1-40% of a softening agent, 0.1-5% of a stabilizer, 0.01-1% of a preservative and the balance of water. By the nano composition, transdermal co-transportation of multi-target hair loss prevention active components is realized, and the nano composition deepens into hair follicles, is synergistic, has double effects of preventing hair loss and promoting hair growing, and can be widely applied to cosmetics for preventing hair loss and promoting hair growing.

The invention discloses application of a camellia oleifera peel extract. The camellia oleifera peel extract serving as a 5-alpha-reductase inhibitor can be used for preparing medicaments for treating prostatitis, benign prostatic hyperplasia and prostate cancers medicaments or daily health products for treating acnes or medicaments or daily health products for treating androgenetic alopecia.

The invention provides a 5-alpha reductase inhibitor-nettle diffractive cyclolignan anthocyanin C, a preparation method and application thereof. The preparation method comprises the following steps: taking the underground part of urtica triangularis as raw material; ethanol extracting; mix suspending ethanol extractive with hot water; extracting petroleum ether, ethyl acetate and water saturated n-butyl alcohol; separating raffinate layer of extractive with macroporous resin and eluting; and separating and purifying by means of silica gel column chromatography. The nettle diffractive cyclolignan anthocyanin C can obviously inhibit the generation of DHT, wherein the effect is as the same as positive finasteride, and has potential use for the prevention and the treatment of prostate disease. The invention takes the diffractive cyclolignan anthocyanin as the raw material which is the root of a pure natural plant, and is safely and easily obtained, has simple and convenient operation, does not introduce toxic substances; has low cost, has strong effect although from the plant, and has very important meanings for developing an anti-benign prostatic hyperplasia medicine.

An application of galanga galangal fruit and its extract in preparing 5 alpha-reductase inhibitor and the medicines for treating prostatoplasia with high curative effect is disclosed.

The invention relates to the field of hair care and recuperation, in particular to an anti-hair loss and hair growth preparation. According to mass percentage, the preparation includes 0.05-5% of dihydrosphinganine. Through testing, the present invention can transform the hair from the terminal growth phase to the initial growth phase within 8 weeks, improve the health of the scalp by balancing the microbial community, enhance the regenerative ability of the scalp, and balance the hair growth cycle by inhibiting 5-α-reductase. Maintains hair in anagen phase to prevent hair loss.

The invention discloses novel endocrine treatment phytochemicals which affect androgenic status. The method for treatment of 5-alpha-reductase responsive diseases using four novel 5-alpha-reductase inhibitor compounds; leucoanthocyanidin, glabrene, glabridin, and alpha-terpineol is disclosed. Glabridin does not interfere with normal testosterone to androgen receptor binding.

The invention relates to a long-acting injection preparation of sterides 5 alpha-reductase inhibitor and a preparation method thereof. The long-acting injection preparation of sterides 5 alpha-reductase inhibitor contains the sterides 5 alpha-reductase inhibitor as a medicinal active component, a pharmaceutically acceptable and biodegradable controlled release auxiliary material and a solvent. The long-acting injection provided by the invention can dispense with the inconvenience of oral dosing for a long time or mistakes in medication, medicines used to be taken twice per day or once per day are taken once per several weeks or once per several months, and also the blood concentration in a human body is kept in an effective concentration range for several weeks or for several months without frequent medication, thus meeting the medication requirements of oblivious aged patients who are inconvenient to move and take many medicines per day, patients with dysphagia or bedridden patients.

The invention discloses a composition to prevent and treat hair loss, comprising Chinese herb 5-alpha reductase inhibitor, an antibacterial agent and a hair loss preventive, wherein the Chinese herb 5-alpha reductase inhibitor includes one or more of nutmeg extract, biochanin, root extract of red ginseng, and Cuscuta reflexa extract. After being applied to cosmetics, the composition enables the scalp to be healthier and effectively prevents and treats hair loss through the route of inhibiting and killing bacteria, inhibiting 5-alpha reductase and promoting hair growth.

The present invention relates to a pharmaceutical composition comprising dutasteride and propylene glycol monolaurate, which improves the stability of dutasteride, which is a poorly soluble drug as a 5-alpha reductase inhibitor, and a process for its preparation. More particularly, the present invention also relates to a capsule formulation which is smaller in size than a commercial dutasteride capsule formulation (AVODART®), but has the equivalent dissolution rate by preparing a pharmaceutical composition comprising propylene glycol monolaurate and dutasteride, which can improve the stability of the dutasteride. A dutasteride formulation having enhanced patient's compliance and improved stability and a method for producing the same are provided.

The invention discloses phenylpropanoid compounds as well as a preparation method and an application thereof. The phenylpropanoid compounds are separated from Swertia atroviolacea, are named 3-hydroxy-1-(6-hydroxymethyl-1,3-dihydroisobenzofuran-5-yl)propan-1-one and have the structural formula shown in the specification, and a molecular formula of the phenylpropanoid compounds is C12H14O4. The preparation method of the phenylpropanoid compounds comprises the following steps: the Swertia atroviolacea is taken as the raw material and subjected to extract extraction, MCI decoloration, silica gel column chromatography and HPLC (high performance liquid chromatography) separation. 5 alpha-reductase activity tests prove that the phenylpropanoid compounds have better inhibition function on 5 alpha-reductase. The invention further discloses the preparation method and the application of the phenylpropanoid compounds. The compounds are simple in structure, have better 5 alpha-reductase inhibition function and can serve as lead compounds for preparing 5 alpha-reductase inhibitors.

A composition for use in the treatment and/or prophylactic treatment of breast cancer includes a 5-Alpha Reductase Inhibitor (5-ARI) and an excipient.

Provided are a composite preparation and a method for producing same, the composite preparation comprising: a core containing a first active ingredient; and a film coating layer containing a 5-alpha-reductase inhibitor, wherein the film coating layer is coated with a film coating solution which is a mixed solvent of water and organic solvent with a ratio of 30-80 wt% of the latter, and in which film coating material dissolved.